EVOTEQ Expands Global Reach with Strategic Partnership with Digital Access to Finance (DAF) for Medicine Traceability and Patient Safety
EVOTEQ, a leader in advanced supply chain solutions, has announced a strategic partnership with Digital Access to Finance (DAF), the Egyptian company responsible for managing the implementation and operation of the Egyptian Drug Authority’s national track-and-trace system. This collaboration aims to bring an innovative solution to Egypt, enhancing medicine traceability, improving patient safety, combating counterfeit drugs, and managing drug shortages.
The partnership was formalized through the signing of a Memorandum of Understanding (MOU) on the third day of Arab Health 2025, held at the Dubai World Trade Center. This agreement builds on EVOTEQ’s successful track record in revolutionizing healthcare traceability systems in the UAE.
Eng. Hatem Kandeel, Founder and Managing Director of DAF, emphasized the significance of the collaboration: “This partnership reflects our commitment to adopting world-class innovations that safeguard patient health and strengthen Egypt’s healthcare ecosystem. Integrating cutting-edge solutions within our systems, in collaboration with EVOTEQ, ensures that every step of the healthcare supply chain is secure, efficient, transparent, and will add value to the pharmaceutical manufacturing field in Egypt. Once we launch in Egypt, we foresee expanding across MENA and Africa as the established service providers in pharmaceutical regulation.”
Jihad Tayara, CEO of EVOTEQ, shared his thoughts on the partnership: “Our collaboration with DAF Egypt is more than a partnership; it’s a shared mission to elevate healthcare standards and protect lives. By extending our capabilities to Egypt, we are addressing critical challenges in medicine authentication and laying the foundation for a future where trust and transparency are at the core of every healthcare system.”
The partnership aims to revolutionize Egypt’s healthcare supply chain by enabling the Egyptian Drug Authority to monitor and validate medicines with unparalleled precision. The joint efforts build on EVOTEQ’s previous successes in the UAE in combating counterfeit medicines, optimizing supply chains, and ensuring that patients receive safe, authentic treatments.
This MoU is a bold step toward fostering a safer and more innovative healthcare ecosystem across the MENA region and Africa. By combining EVOTEQ’s expertise in secure supply chain solutions with DAF Egypt’s leadership in regulatory systems, this collaboration is set to redefine global standards in medicine traceability and patient care.
